166 related articles for article (PubMed ID: 17236889)
1. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience.
Batisky DL; Sorof JM; Sugg J; Llewellyn M; Klibaner M; Hainer JW; Portman RJ; Falkner B;
J Pediatr; 2007 Feb; 150(2):134-9, 139.e1. PubMed ID: 17236889
[TBL] [Abstract][Full Text] [Related]
2. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
Frishman WH; Hainer JW; Sugg J;
Am J Hypertens; 2006 Apr; 19(4):388-95. PubMed ID: 16580575
[TBL] [Abstract][Full Text] [Related]
3. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination.
Papademetriou V; Hainer JW; Sugg J; Munzer D;
Am J Hypertens; 2006 Dec; 19(12):1217-25. PubMed ID: 17161766
[TBL] [Abstract][Full Text] [Related]
4. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
5. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
7. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
8. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
9. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol.
Yilmaz MB; Erdem A; Yalta K; Turgut OO; Yilmaz A; Tandogan I
Adv Ther; 2008 Sep; 25(9):871-83. PubMed ID: 18758699
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the trough-to-peak ratio of cardio-selective beta-blockers in patients with newly diagnosed hypertension.
Soucek M; Rihacek I; Frana P
Blood Press Monit; 2006 Dec; 11(6):337-42. PubMed ID: 17106318
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
12. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
15. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
[TBL] [Abstract][Full Text] [Related]
16. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
19. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
20. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]